Pliant Therapeutics (NASDAQ:PLRX) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a report released on Friday morning, Briefing.com reports. The firm issued an overweight rating and a $41.00 price objective on the stock. Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. boosted their […]

Leave a Reply

Your email address will not be published.

Previous post Lululemon Athletica (NASDAQ:LULU) Price Target Increased to $500.00 by Analysts at JPMorgan Chase & Co.
Next post Toll Brothers (NYSE:TOL) Price Target Raised to $120.00